{'fraction_non_alphanumeric': 0.026343519494204427, 'fraction_numerical': 0.022128556375131718, 'mean_word_length': 5.462585034013605, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Outcomes of living kidney donors with monoclonal gammopathy of undetermined significance

Here, we report outcomes of four cases of living kidney donors with history of monoclonal gammopathy of undetermined significance (MGUS) at Mayo Clinic, Rochester, Rochester, MN between January 2000 and September 2014. The number of patients with end-stage kidney disease (ESRD) awaiting transplantation in the United States (U.S.) has increased over time, by 3000 to 4000 patients each year. 1 Data on safety outcomes of living kidney donors are required to increase public confidence in the transplantation system. MGUS is a common asymptomatic premalignant clonal plasma cell or lymphoplasmacytic proliferative disorder, occurring in more than 3% of the general population over the age of 50. 2 Since patients with MGUS can progress to more advanced diseases (multiple myeloma, immunoglobulin light chain (AL) amyloidosis, light chain deposition disease in